208 related articles for article (PubMed ID: 36639568)
1. The identification of metabolites from gut microbiota in NAFLD via network pharmacology.
Oh KK; Gupta H; Min BH; Ganesan R; Sharma SP; Won SM; Jeong JJ; Lee SB; Cha MG; Kwon GH; Jeong MK; Hyun JY; Eom JA; Park HJ; Yoon SJ; Choi MR; Kim DJ; Suk KT
Sci Rep; 2023 Jan; 13(1):724. PubMed ID: 36639568
[TBL] [Abstract][Full Text] [Related]
2. The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study.
Oh KK; Yoon SJ; Lee SB; Lee SY; Gupta H; Ganesan R; Sharma SP; Won SM; Jeong JJ; Kim DJ; Suk KT
J Transl Med; 2023 Apr; 21(1):263. PubMed ID: 37069607
[TBL] [Abstract][Full Text] [Related]
3. The identification of metabolites from gut microbiota in coronary heart disease via network pharmacology.
Zhou HM; Yang XY; Yue SJ; Wang WX; Zhang Q; Xu DQ; Li JJ; Tang YP
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):145-155. PubMed ID: 38412071
[TBL] [Abstract][Full Text] [Related]
4. New insight into gut microbiota-derived metabolites to enhance liver regeneration via network pharmacology study.
Oh KK; Choi I; Gupta H; Raja G; Sharma SP; Won SM; Jeong JJ; Lee SB; Cha MG; Kwon GH; Jeong MK; Min BH; Hyun JY; Eom JA; Park HJ; Yoon SJ; Choi MR; Kim DJ; Suk KT
Artif Cells Nanomed Biotechnol; 2023 Dec; 51(1):1-12. PubMed ID: 36562095
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of Prebiotics, Probiotics, Postbiotics, and Target from Gut Microbiota to Alleviate Obesity via Network Pharmacology Study.
Oh KK; Gupta H; Min BH; Ganesan R; Sharma SP; Won SM; Jeong JJ; Lee SB; Cha MG; Kwon GH; Jeong MK; Hyun JY; Eom JA; Park HJ; Yoon SJ; Choi MR; Kim DJ; Suk KT
Cells; 2022 Sep; 11(18):. PubMed ID: 36139478
[TBL] [Abstract][Full Text] [Related]
6. The seamless integration of dietary plant-derived natural flavonoids and gut microbiota may ameliorate non-alcoholic fatty liver disease: a network pharmacology analysis.
Oh KK; Gupta H; Ganesan R; Sharma SP; Won SM; Jeong JJ; Lee SB; Cha MG; Kwon GH; Jeong MK; Min BH; Hyun JY; Eom JA; Park HJ; Yoon SJ; Choi MR; Kim DJ; Suk KT
Artif Cells Nanomed Biotechnol; 2023 Dec; 51(1):217-232. PubMed ID: 37129458
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the potential mechanism of the Shugan Xiaozhi decoction for the treatment of nonalcoholic fatty liver disease based on network pharmacology, molecular docking and molecular dynamics simulation.
Yang R; Yang H; Jiang D; Xu L; Feng L; Xing Y
PeerJ; 2022; 10():e14171. PubMed ID: 36389420
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
9. Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease.
Oh KK; Choi YR; Gupta H; Ganesan R; Sharma SP; Won SM; Jeong JJ; Lee SB; Cha MG; Kwon GH; Kim DJ; Suk KT
Curr Issues Mol Biol; 2022 Jul; 44(7):3253-3266. PubMed ID: 35877448
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of Ginkgo biloba in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease based on network pharmacology, molecular docking, and experimental evaluations.
Xu S; Tang L; Qian X; Wang Y; Gong J; Yang H; Su D
J Food Biochem; 2022 Dec; 46(12):e14419. PubMed ID: 36121703
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism of Triclosan in the Treatment of Nonalcoholic Fatty Liver Disease Based on Network Pharmacology].
Zuo C; Sun DL; Zhao TH; Wang JJ; Zhang ZZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):253-261. PubMed ID: 35538760
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Cynarine for treatment of non-alcoholic fatty liver disease based on the integration of network pharmacology, molecular docking and cell experiment.
Sun CY; Yang LL; Zhao P; Yan PZ; Li J; Zhao DS
Hereditas; 2022 Dec; 159(1):44. PubMed ID: 36451177
[TBL] [Abstract][Full Text] [Related]
13. Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation.
Wang L; Zhi Y; Ye Y; Zhang M; Ma X; Tie H; Ma X; Zheng N; Xia W; Song Y
Biomed Res Int; 2020; 2020():8829346. PubMed ID: 33415161
[TBL] [Abstract][Full Text] [Related]
14. Research on the Mechanism of Qushi Huayu Decoction in the Intervention of Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Molecular Docking Technology.
Gao SS; Sun JJ; Wang X; Hu YY; Feng Q; Gou XJ
Biomed Res Int; 2020; 2020():1704960. PubMed ID: 33204683
[TBL] [Abstract][Full Text] [Related]
15. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
16.
Zhao W; Guo M; Feng J; Gu Z; Zhao J; Zhang H; Wang G; Chen W
Nutrients; 2022 Apr; 14(9):. PubMed ID: 35565666
[TBL] [Abstract][Full Text] [Related]
17. Network pharmacology-based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease.
Liu H; Xu J; Li H; Zhang L; Xu P
Anat Rec (Hoboken); 2021 Nov; 304(11):2605-2619. PubMed ID: 34536264
[TBL] [Abstract][Full Text] [Related]
18. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
Ji Y; Yin Y; Li Z; Zhang W
Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
[TBL] [Abstract][Full Text] [Related]
19. Identification of renal protective gut microbiome derived-metabolites in diabetic chronic kidney disease: An integrated approach using network pharmacology and molecular docking.
Saranya GR; Viswanathan P
Saudi J Biol Sci; 2024 Aug; 31(8):104028. PubMed ID: 38854894
[TBL] [Abstract][Full Text] [Related]
20. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
